Cargando…

Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor

BACKGROUND: Ivacaftor is the first cystic fibrosis transmembrane conductance regulator (CFTR) modulator demonstrating clinical benefit in patients with cystic fibrosis (CF). As ivacaftor is intended for chronic, lifelong use, understanding long-term effects is important for patients and healthcare p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bessonova, Leona, Volkova, Nataliya, Higgins, Mark, Bengtsson, Leif, Tian, Simon, Simard, Christopher, Konstan, Michael W, Sawicki, Gregory S, Sewall, Ase, Nyangoma, Stephen, Elbert, Alexander, Marshall, Bruce C, Bilton, Diana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Cystic Fibrosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204955/ https://www.ncbi.nlm.nih.gov/pubmed/29748252 http://dx.doi.org/10.1136/thoraxjnl-2017-210394

Ejemplares similares

Registry-based study in people with cystic fibrosis and an R117H variant treated with ivacaftor
por: Higgins, Mark, et al.
Publicado: (2023)

Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials
por: Keogh, Ruth H, et al.
Publicado: (2022)

ROCK STUDY in CF: sustained anti-inflammatory effects of lumacaftor–ivacaftor in sputum and peripheral blood samples of adult patients with cystic fibrosis—an observational study
por: Arooj, Parniya, et al.
Publicado: (2023)

Burden of cystic fibrosis in children <12 years of age prior to the introduction of CFTR modulator therapies
por: Bresnick, Kathryn, et al.
Publicado: (2021)

Adherence to cystic fibrosis transmembrane conductance regulator (CFTR) modulators: analysis of a national specialty pharmacy database
por: Mehta, Zumi, et al.
Publicado: (2021)

Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals
por: Almulhem, Maryam, et al.
Publicado: (2022)

Randomised cross-over trial evaluating the short-term effects of non-invasive ventilation as an adjunct to airway clearance techniques in adults with cystic fibrosis
por: Stanford, Gemma, et al.
Publicado: (2019)

Acceptability of patient reported outcome measures (PROMs) in a cystic fibrosis data registry
por: Ratnayake, Irushi, et al.
Publicado: (2021)

Investigating outcome measures for assessing airway clearance techniques in adults with cystic fibrosis: protocol of a single-centre randomised controlled crossover trial
por: Stanford, Gemma, et al.
Publicado: (2020)

Impact of newborn screening on outcomes and social inequalities in cystic fibrosis: a UK CF registry-based study
por: Schlüter, Daniela K, et al.
Publicado: (2020)

Lung function in children with cystic fibrosis in the USA and UK: a comparative longitudinal analysis of national registry data
por: Schlüter, Daniela K, et al.
Publicado: (2022)

Emulated trial investigating effects of multiple treatments: estimating combined effects of mucoactive nebulisers in cystic fibrosis using registry data
por: Granger, Emily, et al.
Publicado: (2023)

Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design
por: Jain, Raksha, et al.
Publicado: (2022)

Intestinal current measurement and nasal potential difference to make a diagnosis of cases with inconclusive CFTR genetics and sweat test
por: Minso, Rebecca, et al.
Publicado: (2020)

International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety
por: Quittner, Alexandra L, et al.
Publicado: (2016)

Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis
por: Alton, Eric W F W, et al.
Publicado: (2017)

Eradication of Pseudomonas aeruginosa in adults with cystic fibrosis
por: Kenny, S L, et al.
Publicado: (2014)

Coil embolisation for massive haemoptysis in cystic fibrosis
por: Dohna, Martha, et al.
Publicado: (2021)

Delayed neutrophil apoptosis enhances NET formation in cystic fibrosis
por: Gray, Robert D, et al.
Publicado: (2018)

Increased extracellular vesicles mediate inflammatory signalling in cystic fibrosis
por: Useckaite, Zivile, et al.
Publicado: (2020)

Viability of Pseudomonas aeruginosa in cough aerosols generated by persons with cystic fibrosis
por: Knibbs, Luke D, et al.
Publicado: (2014)

CNS imaging studies in cystic fibrosis patients presenting with sudden neurological events
por: Ellis, Samantha, et al.
Publicado: (2019)

Is chest CT useful in newborn screened infants with cystic fibrosis at 1 year of age?
por: Thia, Lena P, et al.
Publicado: (2014)

Porphyromonas, a potential predictive biomarker of Pseudomonas aeruginosa pulmonary infection in cystic fibrosis
por: Keravec, Marlène, et al.
Publicado: (2019)

Impact of cystic fibrosis on birthweight: a population based study of children in Denmark and Wales
por: Schlüter, Daniela K, et al.
Publicado: (2019)

Longitudinal lung clearance index and association with structural lung damage in children with cystic fibrosis
por: Svedberg, Marcus, et al.
Publicado: (2023)

Evolution of lung function during the first year of life in newborn screened cystic fibrosis infants
por: Nguyen, The Thanh-Diem, et al.
Publicado: (2014)

Shortened Lung Clearance Index is a repeatable and sensitive test in children and adults with cystic fibrosis
por: Hannon, David, et al.
Publicado: (2014)

How can we relieve gastrointestinal symptoms in people with cystic fibrosis? An international qualitative survey
por: Smith, Sherie, et al.
Publicado: (2020)

Variation in treatment preferences of pulmonary exacerbations among Australian and New Zealand cystic fibrosis physicians
por: Currie, Grace, et al.
Publicado: (2021)

Longitudinal assessment of lung clearance index to monitor disease progression in children and adults with cystic fibrosis
por: Horsley, Alex R, et al.
Publicado: (2022)

Cough-generated aerosols of Pseudomonas aeruginosa and other Gram-negative bacteria from patients with cystic fibrosis
por: Wainwright, C E, et al.
Publicado: (2009)

Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age
por: Byrnes, Catherine Ann, et al.
Publicado: (2013)

Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis
por: Dorkin, Henry L, et al.
Publicado: (2015)

Associations between genetics, medical status, physical exercise and psychological well-being in adults with cystic fibrosis
por: Backström-Eriksson, Lena, et al.
Publicado: (2016)

Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection
por: Clancy, J P, et al.
Publicado: (2013)

What effective ways of motivation, support and technologies help people with cystic fibrosis improve and sustain adherence to treatment?
por: Calthorpe, Rebecca J, et al.
Publicado: (2020)

Feasibility of dynamic chest radiography to calculate lung volumes in adult people with cystic fibrosis: a pilot study
por: FitzMaurice, Thomas Simon, et al.
Publicado: (2023)

Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial
por: Nichols, David P, et al.
Publicado: (2022)

Survival models to support shared decision-making about advance care planning for people with advanced stage cystic fibrosis
por: Hajizadeh, Negin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pc8darti9eob5ufmm5bgdotrf8